Here you'll find up-to-date product-related, financial, and partnership-focused communications.
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
European Medicines Agency Grants Orphan Drug Designation for Xeris’ Investigational Ready-to-Use Glucagon for the Treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
Xeris Pharmaceuticals Releases Additional Phase 3 Clinical Trial Data on Its Ready-to-Use Liquid Glucagon Pen
Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
Xeris Pharmaceuticals Announces FDA Acceptance for Review of NDA for Its Ready-to-Use Glucagon Rescue Pen
Xeris Pharmaceuticals and OHSU Conducting Artificial Pancreas Clinical Trial Using Xeris’ Novel Ready-to-Use Liquid Glucagon
Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights
Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences
Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team
Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Xeris Pharmaceuticals Announces Positive Phase 3 Clinical Trial Data on Its Investigational Ready-to-Use Glucagon Rescue Pen
College Diabetes Network Announces Partnership with Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc. Appoints John P. Schmid to Board of Directors
Xeris Pharmaceuticals Announces New Results From Ready-To-Use Liquid Glucagon Clinical Development Program
Xeris Pharmaceuticals’ Ready-to-Use Liquid Glucagon Clinical Data to Be Presented at American Diabetes Association 77th Scientific Sessions
Xeris Pharmaceuticals Announces Closing of $30 Million Financing
Xeris Pharmaceuticals Announces Appointment of Paul R. Edick as President and CEO
Xeris Pharmaceuticals, Inc. to Present G-Pen Human Factors Study Results at 2016 ATTD Meeting
Xeris Pharmaceuticals Announces $41 Million Series C Financing
You have chosen a link to an external site.By clicking "ok", a new window will open.
Do you wish to continue?
Not opening? Check to see you have pop-ups enabled or copy link below in a new window.